



Today, Bertin Pharma, a subsidiary of Bertin Technologies, a CNIM Group entity, announced the sale of its pharmaceutical and biotech services operations to two French companies specialized in the field.

The operations relating to the supply of bioanalysis tools and biological reagents for Defense and Life Sciences will remain at Bertin Pharma.

Montigny-le-Bretonneux – 31 August 2017 - Bertin Pharma has announced the sale of its pharmaceutical development operations (sites at Artigues-près-Bordeaux and Martillac) to Amatsigroup and the sale of its pre-clinical and clinical research operations carried out at the other sites to the Oncodesign Group.

Through these sales of services operations in the pharmaceuticals/biotech sector, the CNIM Group aims to focus on strategic areas which are more closely in line with its core industrial business in the fields of energy, the environment, defense and security. The quality and ambition of both purchasers also look set to boost the development prospects of the Bertin Pharma operations and the teams involved.

The other staff working primarily on bioanalysis and biodefense tools will continue their work at Bertin Pharma, in close collaboration with the teams at Bertin Technologies.

About Bertin Technologies: www.bertin-technologies.com

Bertin Technologies, a subsidiary of CNIM Group, relies on its long history of innovation to develop, produce and market innovative systems and equipment worldwide. With close to €96 million in revenues and 700 employees in 2016, of which 2/3 are engineers and high-level managers, Bertin Technologies and its subsidiaries work in four major fields: Systems and Instrumentation, Consulting and Engineering, Information Technology and Pharmaceuticals and Biotech. Based in the Paris region, the company is active worldwide.

About CNIM: www.cnim.com

The CNIM Group designs, develops and manufactures turnkey industrial solutions with high technological content and provides expertise and services in the areas of the Environment, Energy, Defense and High Technology. CNIM manages projects and sells equipment throughout the world. CNIM is backed by a stable family shareholder base that underpins its future development. The Group employs 2,500 staff and had revenues of €539.9 million in 2016, 54.6% of which was from exports. CNIM is listed on the Euronext Paris stock exchange.

About Amatsi: www.amatsigroup.com

Amatsigroup is a company specializing in pharmaceutical development which operates on a portfolio of 300 international clients, pharmaceutical groups and biotechnology companies. Since 2010, Amatsigroup has pursued its strategy of international growth (creation of an entity in the United States in 2014 followed by two acquisitions in Belgium), the expansion of its portfolio of services relating to biological drugs and the extension of its operational capacity in pharmaceutical analysis, formulation, galenic development and the manufacture of small production clinical and commercial batches. In 2016, the company achieved revenues of €45 million and had over 350 highly qualified Life Sciences staff. The majority shareholder of Amatsigroup has been Ekkio Capital, alongside the company's management, since the start of 2011. An exclusive agreement was signed with Eurofins, in July 2017, for the sale of the Amatsigroup.

About the Oncodesign group: www.oncodesign.com/

Founded over 20 years ago by Dr. Philippe Genne, the company's CEO and major shareholder, Oncodesign is a biotechnology company specialized in precision medicine. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, and advanced medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled several promising molecules with substantial therapeutic potential to be targeted, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 165 employees and subsidiaries in Canada and the USA.

Press contacts

CNIM, Bertin Technologies and Bertin Pharma	Amatsigroup	Oncodesign
Gootenberg Press Agency	Citigate Dewe Rogerson	NewCap
François Ramaget Tel.: +33 (0)1 43 59 29 92 Email: francois.ramaget@gootenberg.fr	Daiana Hirte Tel.: +33 (0)1 53 32 78 90 Email: daiana.hirte@citigate.fr	Investor relations and press office Julien Perez / Nicolas Merigeau Tel.: +33 (0)1 44 71 98 52 Email: oncodesign@newcap.eu
Laurence Colin Tel.: +33 (0)1 43 59 00 46 Email: laurence.colin@gootenberg.fr		